Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 23, 2019

NIMH funds clinical research to improve Schizophrenia treatment

The National Institutes of Mental Health (NIMH) has granted $7.3m to researchers at the Feinstein Institutes for Medical Research to support their efforts to provide improved treatment for schizophrenia.

The National Institutes of Mental Health (NIMH) has granted $7.3m to researchers at the Feinstein Institutes for Medical Research to support their efforts to provide improved treatment for schizophrenia.

The schizophrenia clinical research study is led by Dr John Kane and Dr Delbert Robinson under the name ‘Early-phase Schizophrenia: Practice-based Research to Improve Treatment Outcomes (ESPRITO).’

Schizophrenia is a serious mental illness and brain disabling chronic disorder that impacts a persons ability to control their emotions.

It is also defined by disorganised thinking and abnormal social behaviour, as well as disturbances in perceptions.

Feinstein Institutes Institute of Behavioral Science professor and schizophrenia researcher Dr John Kane said: “We are excited to build off of our previous work to develop improved and more uniform services for early intervention in schizophrenia.

Feinstein Institutes associate professor Dr Robinson said: “With this new clinical research, we aim to improve treatment strategies and medication adherence and help patients continue to receive the care they need to get back to their everyday lives.”

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

With the help of ESPRITO programme, 11 clinics across four states will provide the NAVIGATE model of coordinated speciality care. The application of standard measurement and data gathering will help in providing enhanced treatment quality, consistency, and response.

The NIMH-funded clinical research will enable researchers to address hurdles in early-phase intervention and reduce hospitalisations, preventing patients from discontinuing the clinical study phase and improving overall outcomes.

Feinstein Institutes president and CEO Kevin Tracey said: “NIH support of early-phase schizophrenia research is in the national interest.

“Doctors Kane and Robinson’s research offers hope for patients to achieve a better quality of life.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU